Carlos Navarrete, Mariana Macedo, Rachael Colley, Jingling Zhang, Nicole Ferrada, Maria Eduarda Mello, Rodrigo Lira, Carmelo Bastos-Filho, Umberto Grandi, Jérôme Lang & César A. Hidalgo 

Nature Human Behaviour (2023)

Digital technologies can augment civic participation by facilitating the expression of detailed political preferences. Yet, digital participation efforts often rely on methods optimized for elections involving a few candidates. Here we present data collected in an online experiment where participants built personalized government programmes by combining policies proposed by the candidates of the 2022 French and Brazilian presidential elections. We use this data to explore aggregates complementing those used in social choice theory, finding that a metric of divisiveness, which is uncorrelated with traditional aggregation functions, can identify polarizing proposals. These metrics provide a score for the divisiveness of each proposal that can be estimated in the absence of data on the demographic characteristics of participants and that explains the issues that divide a population. These findings suggest that divisiveness metrics can be useful complements to traditional aggregation functions in direct forms of digital participation.

Read the full article at: www.nature.com

KISHORE VASAN, DEISY MORSELLI GYSI, ALBERT-LÁSZLÓ BARABÁSI

iScience 26, 108361

The depth of knowledge offered by post-genomic medicine has carried the promise of new drugs, and cures for multiple diseases. To explore the degree to which this capability has materialized, we extract meta-data from 356,403 clinical trials spanning four decades, aiming to offer mechanistic insights into the innovation practices in drug discovery. We find that convention dominates over innovation, as over 96% of the recorded trials focus on previously tested drug targets, and the tested drugs target only 12% of the human interactome. If current patterns persist, it would take 170 years to target all druggable proteins. We uncover two network-based fundamental mechanisms that currently limit target discovery: preferential attachment, leading to the repeated exploration of previously targeted proteins; and local network effects, limiting exploration to proteins interacting with highly explored proteins. We build on these insights to develop a quantitative network-based model to enhance drug discovery in clinical trials.

Read the full article at: www.cell.com